– SINGAPORE, Singapore – HistoIndex today announced the appointment of Dr. David John Jeans CBE, as Non-Executive Chairman of the Board of Directors effective from 6th December 2022, replacing Sim Giok Lak who stepped down as Board Chairman but remains as a Non-Executive Director on the Board as well as Non-Executive Chairman of the wholly owned subsidiary, Choutu Technology.
“Dr. John Jeans, a renowned thought leader and visionary in the healthcare industry will continue with the foundation that Mr. Sim had laid down as we continue our growth trajectory as a leading AI digital pathology company,” said CEO, Dr. Gideon Ho.
About Dr. David John Jeans
Dr. David John Jeans was first appointed to the Board as a non-executive director on 17th May 2022. Dr Jeans has helmed senior leadership positions in international healthcare corporations such as Bristol Myers Squibb and Johnson & Johnson. He was previously the Chairman of Cardiff University, Deputy Chief Executive of the UK Medical Research Council, chaired the Trustee Board of MRC Technology, involved in the Science Advisory Council for Wales, and served as Trustee of the Francis Crick Institute. He is currently the Chairman of the Digital Health & Care Innovation Centre in Scotland and in Singapore, John is a co-Chair of the Strategic Advisory Panel at the Diagnostics Development Hub (DxD Hub). In 2012, John was awarded the Commander of the Order of the British Empire (CBE) for his significant contributions to Life Sciences, Healthcare and Science.
Dr. David John Jeans said, ”I am excited to be appointed as the Non-Executive Chairman of the Board. Coupling HistoIndex’s proprietary stain-free imaging and machine-learning algorithm in fibrosis and cancers, we are confident of initiating better outcomes for drug development and patient care.”
About HistoIndex
Founded in Singapore, HistoIndex is a leading MedTech/Healthcare company that specializes in its proprietary integrated stain-free AI digital pathology platform. Enabled by Second Harmonic Generation and Two-Photon Excitation along with automated imaging analysis algorithms, the integrated platform accurately quantifies histological features and fine measurements that are critical for the evaluation of therapeutic efficacy in clinical trials. The stain-free AI platform is currently involved in multiple FDA clinical trials for Nonalcoholic Steatohepatitis. In addition, it has benefitted more than 150 research and academic institutes, CROs and biopharma companies around the world in drug discovery and development efforts for fibrotic diseases and cancers.
For more information: https://www.histoindex.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
